Evidence-Based Medicine
Copyright ©The Author(s) 2016.
World J Gastrointest Surg. Oct 27, 2016; 8(10): 713-718
Published online Oct 27, 2016. doi: 10.4240/wjgs.v8.i10.713
Table 1 Comparison of studies with their design and outcomes
Ref.Design of studySample sizeDuration of treatmentResults
Akriviadis et al[4]Randomized controlled trialn = 53 Group I (n = 26) (NSAID) Group II (n = 27) (Placebo)3 dSuperior results from Diclofenac usage
Tomida et al[5]Non-randomized controlled trialn = 527Ursodeoxycholic acid a safe option in symptomatic but high surgical risk patients
Dula et al[6]Randomized controlled trialn = 30 Group I (n = 15) (NSAID) Group II (n = 15) (Meperidine)1 dComparable efficacy but lesser side-effects from Ketorolac
Henderson et al[7]Randomized controlled trialn = 324 Group I (n = 175) (NSAID) Group I (n = 149) (Meperidine)Comparable efficacy but lesser side-effects from Ketorolac
Kumar et al[2]Randomized controlled trialn = 72 Group I (n = 36) (NSAID) Group II (n = 36) (Hyoscine)3 dRapid symptom relief with Diclofenac and lower rate of sequelae
Antevil et al[1]Randomized controlled trialn = 39 Group I (Glycopyrrolate) Group II (Placebo)No significant difference in analgesia between glycopyrrolate and placebo
Olsen et al[9]Randomized controlled trialn = 46 Group I (n = 23) (Ketorolac) Group II (n = 23) (Butorphanol)1 dBoth agents provided reasonable relief of symptoms
Basurto Oña et al[10]Meta-analysisNSAIDs drugs of choice for symptom control and improvement of prognosis